List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11227785/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery and Optimization of 6-(1-Substituted pyrrole-2-yl)- <i>s</i> -triazine Containing Compounds as Antibacterial Agents. ACS Infectious Diseases, 2022, 8, 757-767.	3.8	6
2	Development of Singleâ€Stranded DNA Bisintercalating Inhibitors of Primase DnaG as Antibiotics. ChemMedChem, 2021, 16, 1986-1995.	3.2	2
3	Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from <i>Mycobacterium tuberculosis</i> to overcome kanamycin resistance. RSC Medicinal Chemistry, 2021, 12, 1894-1909.	3.9	9
4	Siderophore-mediated zinc acquisition enhances enterobacterial colonization of the inflamed gut. Nature Communications, 2021, 12, 7016.	12.8	35
5	Structure-Guided Optimization of Inhibitors of Acetyltransferase Eis from <i>Mycobacterium tuberculosis</i> . ACS Chemical Biology, 2020, 15, 1581-1594.	3.4	14
6	Probing the Robustness of Inhibitors of Tuberculosis Aminoglycoside Resistance Enzyme Eis by Mutagenesis. ACS Infectious Diseases, 2019, 5, 1772-1778.	3.8	5
7	Investigating the promiscuity of the chloramphenicol nitroreductase from Haemophilus influenzae towards the reduction of 4-nitrobenzene derivatives. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1127-1132.	2.2	9
8	N,N′-diaryl-bishydrazones in a biphenyl platform: Broad spectrum antifungal agents. European Journal of Medicinal Chemistry, 2019, 164, 273-281.	5.5	13
9	Synthesis, antimicrobial activity, attenuation of aminoglycoside resistance in MRSA, and ribosomal A-site binding of pyrene-neomycin conjugates. European Journal of Medicinal Chemistry, 2019, 163, 381-393.	5.5	13
10	Acetylation by Eis and Deacetylation by Rv1151c of Mycobacterium tuberculosis HupB: Biochemical and Structural Insight. Biochemistry, 2018, 57, 781-790.	2.5	29
11	Derivatives of Ribosome-Inhibiting Antibiotic Chloramphenicol Inhibit the Biosynthesis of Bacterial Cell Wall. ACS Infectious Diseases, 2018, 4, 1121-1129.	3.8	19
12	Potent 1,2,4-Triazino[5,6b]indole-3-thioether Inhibitors of the Kanamycin Resistance Enzyme Eis from Mycobacterium tuberculosis. ACS Infectious Diseases, 2018, 4, 1030-1040.	3.8	23
13	Multifunctional Donepezil Analogues as Cholinesterase and BACE1 Inhibitors. Molecules, 2018, 23, 3252.	3.8	26
14	Interfering With DNA Decondensation as a Strategy Against Mycobacteria. Frontiers in Microbiology, 2018, 9, 2034.	3.5	8
15	Differential Effects of Linkers on the Activity of Amphiphilic Tobramycin Antifungals. Molecules, 2018, 23, 899.	3.8	11
16	Using MbtHâ€Like Proteins to Alter the Substrate Profile of a Nonribosomal Peptide Adenylation Enzyme. ChemBioChem, 2018, 19, 2186-2194.	2.6	23
17	Antimicrobial Activity, AME Resistance, and A-Site Binding Studies of Anthraquinone–Neomycin Conjugates. ACS Infectious Diseases, 2017, 3, 206-215.	3.8	21
18	Combating Enhanced Intracellular Survival (Eis)-Mediated Kanamycin Resistance of <i>Mycobacterium tuberculosis</i> by Novel Pyrrolo[1,5- <i>a</i>]pyrazine-Based Eis Inhibitors. ACS Infectious Diseases, 2017, 3, 302-309.	3.8	45

#	Article	IF	CITATIONS
19	Bis(N-amidinohydrazones) and N-(amidino)-N′-aryl-bishydrazones: New classes of antibacterial/antifungal agents. Bioorganic and Medicinal Chemistry, 2017, 25, 58-66.	3.0	10
20	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. Bioorganic and Medicinal Chemistry, 2016, 24, 6298-6306.	3.0	23
21	Potent Inhibitors of Acetyltransferase Eis Overcome Kanamycin Resistance in <i>Mycobacterium tuberculosis</i> . ACS Chemical Biology, 2016, 11, 1639-1646.	3.4	41
22	A complex game of hide and seek: the search for new antifungals. MedChemComm, 2016, 7, 1285-1306.	3.4	50
23	Discovery and Optimization of Two Eis Inhibitor Families as Kanamycin Adjuvants against Drug-Resistant <i>M. tuberculosis</i> . ACS Medicinal Chemistry Letters, 2016, 7, 1219-1221.	2.8	34
24	Sulfonamide-Based Inhibitors of Aminoglycoside Acetyltransferase Eis Abolish Resistance to Kanamycin in <i>Mycobacterium tuberculosis</i> . Journal of Medicinal Chemistry, 2016, 59, 10619-10628.	6.4	42
25	A biocatalytic approach to capuramycin analogues by exploiting a substrate permissive N-transacylase CapW. Organic and Biomolecular Chemistry, 2016, 14, 3956-3962.	2.8	16
26	Arginine-linked neomycin B dimers: synthesis, rRNA binding, and resistance enzyme activity. MedChemComm, 2016, 7, 164-169.	3.4	20
27	Tobramycin Variants with Enhanced Ribosomeâ€Targeting Activity. ChemBioChem, 2015, 16, 1565-1570.	2.6	20
28	Influence of Linker Length and Composition on Enzymatic Activity and Ribosomal Binding of Neomycin Dimers. Antimicrobial Agents and Chemotherapy, 2015, 59, 3899-3905.	3.2	18
29	Chemically related 4,5-linked aminoglycoside antibiotics drive subunit rotation in opposite directions. Nature Communications, 2015, 6, 7896.	12.8	58
30	The Biosynthesis of Capuramycin-type Antibiotics. Journal of Biological Chemistry, 2015, 290, 13710-13724.	3.4	28
31	Rapid Synthesis, RNA Binding, and Antibacterial Screening of a Peptidic-Aminosugar (PA) Library. ACS Chemical Biology, 2015, 10, 1278-1289.	3.4	35
32	Biochemical and Structural Analysis of an Eis Family Aminoglycoside Acetyltransferase from <i>Bacillus anthracis</i> . Biochemistry, 2015, 54, 3197-3206.	2.5	27
33	Inhibition of Aminoglycoside Acetyltransferase Resistance Enzymes by Metal Salts. Antimicrobial Agents and Chemotherapy, 2015, 59, 4148-4156.	3.2	48
34	Comparative Study of Eis-like Enzymes from Pathogenic and Nonpathogenic Bacteria. ACS Infectious Diseases, 2015, 1, 272-283.	3.8	19
35	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. ACS Medicinal Chemistry Letters, 2015, 6, 1134-1139.	2.8	14
36	Effects of structural modifications on the metal binding, anti-amyloid activity, and cholinesterase inhibitory activity of chalcones. Organic and Biomolecular Chemistry, 2015, 13, 9418-9426.	2.8	29

#	Article	IF	CITATIONS
37	Amphiphilic Tobramycin Analogues as Antibacterial and Antifungal Agents. Antimicrobial Agents and Chemotherapy, 2015, 59, 4861-4869.	3.2	62
38	Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. Journal of Medicinal Chemistry, 2015, 58, 9124-9132.	6.4	54
39	Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG. Journal of Antibiotics, 2015, 68, 153-157.	2.0	36
40	A Random Sequential Mechanism of Aminoglycoside Acetylation by Mycobacterium tuberculosis Eis Protein. PLoS ONE, 2014, 9, e92370.	2.5	24
41	A novel hybrid of 6-chlorotacrine and metal–amyloid-β modulator for inhibition of acetylcholinesterase and metal-induced amyloid-β aggregation. Chemical Science, 2013, 4, 4137.	7.4	48
42	Redesign of Substrate Specificity and Identification of the Aminoglycoside Binding Residues of Eis from Mycobacterium tuberculosis. Biochemistry, 2013, 52, 5125-5132.	2.5	16
43	Discovery of Inhibitors of <i>Bacillus anthracis</i> Primase DnaG. Biochemistry, 2013, 52, 6905-6910.	2.5	24
44	Investigation of the role of linker moieties in bifunctional tacrine hybrids. Bioorganic and Medicinal Chemistry, 2013, 21, 3614-3623.	3.0	14
45	Synthesis and Evaluation of Hetero- and Homodimers of Ribosome-Targeting Antibiotics: Antimicrobial Activity, in Vitro Inhibition of Translation, and Drug Resistance. Journal of Medicinal Chemistry, 2013, 56, 5613-5625.	6.4	35
46	Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes. Journal of Antimicrobial Chemotherapy, 2013, 68, 800-805.	3.0	54
47	Domain dissection and characterization of the aminoglycoside resistance enzyme ANT(3″)-li/AAC(6′)-lld from Serratia marcescens. Biochimie, 2013, 95, 1319-1325.	2.6	14
48	Resistance in tuberculosis: what do we know and where can we go?. Frontiers in Microbiology, 2013, 4, 208.	3.5	40
49	Kinase atalyzed Biotinylation of Peptides, Proteins, and Lysates. Current Protocols in Chemical Biology, 2012, 4, 83-100.	1.7	6
50	Cosubstrate Tolerance of the Aminoglycoside Resistance Enzyme Eis from Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 5831-5838.	3.2	16
51	Aminoglycoside Multiacetylating Activity of the Enhanced Intracellular Survival Protein from <i>Mycobacterium smegmatis</i> and Its Inhibition. Biochemistry, 2012, 51, 4959-4967.	2.5	55
52	Biochemical and structural analysis of aminoglycoside acetyltransferase Eis from Anabaena variabilis. Molecular BioSystems, 2012, 8, 3305.	2.9	32
53	Innentitelbild: 6′′-Thioether Tobramycin Analogues: Towards Selective Targeting of Bacterial Membranes (Angew. Chem. 23/2012). Angewandte Chemie, 2012, 124, 5602-5602.	2.0	0
54	6′′â€Thioether Tobramycin Analogues: Towards Selective Targeting of Bacterial Membranes. Angewandte Chemie - International Edition, 2012, 51, 5652-5656.	13.8	80

#	Article	IF	CITATIONS
55	Inside Cover: 6′′-Thioether Tobramycin Analogues: Towards Selective Targeting of Bacterial Membranes (Angew. Chem. Int. Ed. 23/2012). Angewandte Chemie - International Edition, 2012, 51, 5508-5508.	13.8	0
56	Identification and Characterization of Inhibitors of the Aminoglycoside Resistance Acetyltransferase Eis from <i>Mycobacterium tuberculosis</i> . ChemMedChem, 2012, 7, 73-77.	3.2	55
57	Back Cover: Identification and Characterization of Inhibitors of the Aminoglycoside Resistance Acetyltransferase Eis from Mycobacterium tuberculosis (ChemMedChem 1/2012). ChemMedChem, 2012, 7, 176-176.	3.2	0
58	Assessment of 6â€2- and 6â€2â€2â€2-N-acylation of aminoglycosides as a strategy to overcome bacterial resista Organic and Biomolecular Chemistry, 2011, 9, 4057.	nce. 2.8	32
59	Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase. MedChemComm, 2011, 2, 406.	3.4	29
60	Effects of Altering Aminoglycoside Structures on Bacterial Resistance Enzyme Activities. Antimicrobial Agents and Chemotherapy, 2011, 55, 3207-3213.	3.2	37
61	Exploring the Substrate Promiscuity of Drugâ€Modifying Enzymes for the Chemoenzymatic Generation of Nâ€Acylated Aminoglycosides. ChemBioChem, 2010, 11, 119-126.	2.6	70
62	The Future of Aminoglycosides: The End or Renaissance?. ChemBioChem, 2010, 11, 880-902.	2.6	157
63	Posttranslational Modification of Proteins. , 2010, , 433-468.		2
64	Dissecting the cosubstrate structure requirements of the Staphylococcus aureus aminoglycoside resistance enzyme ANT(4′). Biochemical and Biophysical Research Communications, 2010, 403, 85-90.	2.1	18
65	Redesign of Cosubstrate Specificity and Identification of Important Residues for Substrate Binding to hChAT. Biochemistry, 2010, 49, 6219-6227.	2.5	12
66	Posttranslational Modification of Proteins. , 2010, , 528-559.		0
67	Exploring Kinase Cosubstrate Promiscuity: Monitoring Kinase Activity through Dansylation. ChemBioChem, 2009, 10, 234-237.	2.6	33
68	hChAT: A Tool for the Chemoenzymatic Generation of Potential Acetyl/Butyrylcholinesterase Inhibitors. ChemBioChem, 2009, 10, 2191-2194.	2.6	20
69	Kinase-Catalyzed Biotinylation for Phosphoprotein Detection. Journal of the American Chemical Society, 2007, 129, 10-11.	13.7	103
70	Chapter 7. Emerging Targets in Anti-Tubercular Drug Design. RSC Drug Discovery Series, 0, , 141-203.	0.3	2